322 related articles for article (PubMed ID: 11980672)
1. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
Virtanen SS; Väänänen HK; Härkönen PL; Lakkakorpi PT
Cancer Res; 2002 May; 62(9):2708-14. PubMed ID: 11980672
[TBL] [Abstract][Full Text] [Related]
2. Correspondence Re S. S. Virtanen et al., Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002;62:2708-14. Re K. Sawada et al., Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of Rho. Cancer Res 2002;62:6015-20.
Andela VB
Cancer Res; 2004 Apr; 64(8):2934-5; author reply 2935-6. PubMed ID: 15087415
[No Abstract] [Full Text] [Related]
3. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
4. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RG; Rodan GA; Reszka AA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):133-8. PubMed ID: 9874784
[TBL] [Abstract][Full Text] [Related]
5. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho.
Sawada K; Morishige K; Tahara M; Kawagishi R; Ikebuchi Y; Tasaka K; Murata Y
Cancer Res; 2002 Nov; 62(21):6015-20. PubMed ID: 12414621
[TBL] [Abstract][Full Text] [Related]
6. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells.
Iguchi K; Tatsuda Y; Usui S; Hirano K
Eur J Pharmacol; 2010 Sep; 641(1):35-40. PubMed ID: 20519142
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
8. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Nakamura H
Cancer Res; 2001 Jun; 61(12):4885-91. PubMed ID: 11406567
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor formation by snake venom disintegrin.
Yang RS; Tang CH; Chuang WJ; Huang TH; Peng HC; Huang TF; Fu WM
Toxicon; 2005 Apr; 45(5):661-9. PubMed ID: 15777962
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
[TBL] [Abstract][Full Text] [Related]
15. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho.
Kusama T; Mukai M; Tatsuta M; Nakamura H; Inoue M
Int J Oncol; 2006 Jul; 29(1):217-23. PubMed ID: 16773203
[TBL] [Abstract][Full Text] [Related]
17. Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro.
Muller S; Migianu E; Lecouvey M; Kraemer M; Oudar O
Anticancer Res; 2005; 25(4):2655-60. PubMed ID: 16080508
[TBL] [Abstract][Full Text] [Related]
18. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: involvement of mevalonate pathway, TNFalpha, macrophages, and T-cells.
Deng X; Yu Z; Funayama H; Yamaguchi K; Sasano T; Sugawara S; Endo Y
Int Immunopharmacol; 2007 Feb; 7(2):152-61. PubMed ID: 17178381
[TBL] [Abstract][Full Text] [Related]
19. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines.
Cheng YY; Huang L; Lee KM; Li K; Kumta SM
Pediatr Blood Cancer; 2004 May; 42(5):410-5. PubMed ID: 15049011
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Boissier S; Ferreras M; Peyruchaud O; Magnetto S; Ebetino FH; Colombel M; Delmas P; Delaissé JM; Clézardin P
Cancer Res; 2000 Jun; 60(11):2949-54. PubMed ID: 10850442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
